Dechert Advises the Shareholders of LARALAB GmbH on Sale of LARALAB to Abbott Laboratories

Dechert advised the shareholders of LARALAB GmbH on the successful sale of the Munich-based software startup to Abbott Laboratories.

LARALAB is the developer of heart.ai – the first fully automated, cloud-based solution for pre-screening cardiac interventions. The platform delivers instant screening results without manual workup, significantly improving efficiency in both patient care and clinical trials.

The acquisition will enable LARALAB to accelerate the global rollout of heart.ai, while enhancing Abbott’s digital capabilities across the cardiovascular care pathway.

This transaction underscores Dechert’s deep expertise in complex, technology-driven M&A and the healthcare sector.

The Dechert team that advised on the deal was led by corporate partner Federico Pappalardo, private equity counsel Tobias Hugo and private equity associate Adriana Worms, with support from corporate partner Carina Klaes-Staudt; intellectual property partner Thomas Rayski; cyber and data protection national partner Dr. Olaf Fasshauer; cyber, privacy and AI associate James Smith; and corporate associate Alexa Serafin.

About Dechert

Dechert is the law firm that helps business leaders lead.

For more than 150 years, we have advised clients on critical issues – from high-stakes litigation to first-in-market transaction structures and complex regulatory matters. Our nearly 1,000 lawyers in commercial centers worldwide are immersed in the key sectors we serve – financial services, private capital, real estate, life sciences and technology.

Dechert delivers unwavering partnership so our clients can achieve unprecedented results.